Normal FDG distribution patterns in the head and neck: PET/CT evaluation.

PURPOSE To retrospectively evaluate the distribution of fluorine 18 fluorodeoxyglucose (FDG) in the head and neck region with combined positron emission tomography-computed tomography (PET/CT) in patients with no known abnormality in this region. MATERIALS AND METHODS The institutional review board allowed a retrospective review of PET/CT images obtained in 78 patients with non-head and neck cancer and waived the requirement for informed consent. The accumulation of FDG in 11 normal head and neck structures was visually and quantitatively assessed retrospectively. Positive rate percentage (PRP) was defined as the sum of the percentages of patients with grade 2 and grade 3 tracer uptake intensity. Standardized uptake values (SUVs) were calculated for quantitative analysis. Mean SUVs were compared between the male and female patients by using the unpaired t test, and the correlation between FDG uptake and patient age was assessed by using the Pearson correlation coefficient test. RESULTS Intense tracer uptake was usually seen in the palatine tonsils (PRP, 98%; mean SUV, 3.48), soft palate (PRP, 96%; mean SUV, 3.13), and lingual tonsils (PRP, 96%; mean SUV, 3.11). In the inferior concha (PRP, 4%; mean SUV, 1.56), thyroid gland (PRP, 3%; mean SUV, 1.31), and tongue (PRP, 1%; mean SUV, 1.39), uptake was typically minimal. FDG accumulation was variable in the sublingual glands (PRP, 72%; mean SUV, 2.93), spinal cord (PRP, 64%; mean SUV, 2.12), submandibular glands (PRP, 53%; mean SUV, 2.11), parotid glands (PRP, 51%; mean SUV, 1.90), and vocal cords (PRP, 19%; mean SUV, 1.77). The mean normal-tissue SUV in the soft palate was higher in male than in female patients (P <.01). A negative correlation between age and physiologic FDG uptake was seen in the palatine tonsils (r=-0.51, P <.001) and sublingual glands (r=-0.70, P <.001). CONCLUSION Intense FDG uptake was usually observed in the palatine tonsils, lingual tonsils, and soft palate, whereas uptake in the major salivary glands was variable.

[1]  N. Sadato,et al.  Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  A. Buck,et al.  Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  S. Yasuda,et al.  Chronic thyroiditis: diffuse uptake of FDG at PET. , 1998, Radiology.

[5]  B C Stack,et al.  Surveillance for recurrent head and neck cancer using positron emission tomography. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D J Hawkes,et al.  Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. , 1996, American journal of surgery.

[7]  W N Hanafee,et al.  Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. , 1993, Radiology.

[8]  P. Ell,et al.  Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.

[9]  D. Visvikis,et al.  Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET , 2001, European Journal of Nuclear Medicine.

[10]  M D Blaufox,et al.  PET imaging in oncology. , 2000, Seminars in nuclear medicine.

[11]  D W. Townsend,et al.  Combined PET/CT Imaging in Oncology. Impact on Patient Management. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[12]  M. Izumi,et al.  The MR imaging assessment of submandibular gland sialoadenitis secondary to sialolithiasis: correlation with CT and histopathologic findings. , 1999, AJNR. American journal of neuroradiology.

[13]  Abass Alavi,et al.  Whole-body FDG-PET imaging in the management of patients with cancer. , 2002, Seminars in nuclear medicine.

[14]  M N Maisey,et al.  FDG–PET. A possible prognostic factor in head and neck cancer , 2002, British Journal of Cancer.

[15]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  N. Sadato,et al.  FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. Wahl,et al.  PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  A. Kaim,et al.  PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report. , 2001, Radiology.

[19]  M. Shakudo,et al.  Physiological FDG uptake in the palatine tonsils , 2001, Annals of nuclear medicine.

[20]  R. Wahl,et al.  "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  G. Hör,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer , 1998, European Journal of Nuclear Medicine.